— Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T […]
— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML —
— WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events —
— First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with
— Veteran biopharmaceutical executive Mark Alles brings more than three decades of global hematology and oncology experience, and significant corporate
— Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) — -WU-NK-101 demonstrated
— Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance —
— Kumar Srinivasan Ph.D., M.B.A., Appointed President and Chief Executive Officer — ST. LOUIS, MO and SAN DIEGO, CA, March
— WU-NK-101 overcomes limitations encountered with other adoptive cell therapies in solid tumors — –WU-NK-101 exhibited robust trafficking, intra-tumor infiltration,
— Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell